Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Prevention and Detection of Diabetic Embryopathy

McLeod L.a · Ray J.G.b

Author affiliations

aDepartment of Obstetrics and Gynecology, University of Toronto, and bDivision of Obstetrical Medicine, Department of Medicine, Women’s College Campus, Sunnybrook and Women’s College Health Sciences Centre, Toronto, Canada

Related Articles for ""

Community Genet 2002;5:33–39

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: September 27, 2002
Issue release date: September 2002

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 4

ISSN: 1662-4246 (Print)
eISSN: 1662-8063 (Online)

For additional information: https://www.karger.com/PHG

Abstract

Congenital anomalies are more common in the offspring of women with type 1 and type 2 diabetes mellitus. Herein we define those anomalies more commonly found in the offspring of women with diabetes mellitus, and examine the role of hyperglycemia in their pathogenesis. We then discuss methods for the optimal screening and detection of embryopathy. We conclude by presenting evidence in support of preconception diabetes care to lower the risk of fetal anomalies in women with diabetes mellitus.

© 2002 S. Karger AG, Basel


References

  1. Casson IF, Clarke CA, Howard CV, McKendrick O, Pennycock S, Pharoah POD, et al: Outcomes of pregnancy in insulin-dependent diabetic women: Results of a five-year population cohort study. BMJ 1997;315:275–278.
  2. Mills JL, Knopp RH, Simpson JL, Jovanovic-Peterson L, Metzger BE, Holmes LB, et al: Lack of relation of increased malformation rates in infants of diabetic mothers to glycemic control during pregnancy. N Engl J Med 1988;318:671–676.
  3. Rowland TW, Hubbell JP Jr, Nadas AS: Congenital heart disease in infants of diabetic mothers. J Pediatr 1973;83:815–820.
    External Resources
  4. Albert TJ, Landon MB, Wheller JJ, Samuels P, Cheng RF, Gabbe S: Prenatal detection of fetal anomalies in pregnancies complicated by insulin-dependent diabetes mellitus. Am J Obstet Gynecol 1996;174:1424–1428.
  5. Meyer-Wittkopf M, Simpson JM, Sharland GK: Incidence of congenital heart defects in fetuses of diabetic mothers: A retrospective study of 326 cases. Ultrasound Obstet Gynecol 1996;8:8–10.
  6. Hafner E, Scholler J, Schuchter K, Sterniste W, Philipp K: Detection of fetal congenital heart disease in a low-risk population. Prenat Diagn 1998;18:808–815.
  7. Mills JL, Baker L, Goldman AS: Malformations in infants of diabetic mothers occur before the seventh gestational week. Implications for treatment. Diabetes 1979;28:292–293.
  8. Milunsky A, Alpert E, Kitzmiller JL, Younger MD, Neff RK: Prenatal diagnosis of neural tube defects. 8. The importance of serum α-fetoprotein screening in diabetic pregnant women. Am J Obstet Gynecol 1982;142:1030–1032.
    External Resources
  9. Sadler TW, Hunter ES 3rd, Balkan W, Horton WE Jr: Effects of maternal diabetes on embryogenesis. Am J Perinatol 1988;5:319–326.
    External Resources
  10. Eriksson UJ, Karlsson MG, Styrud J: Mechanisms of congenital malformations in diabetic pregnancy. Biol Neonate 1987;51:113–118.
    External Resources
  11. Freinkel N, Cockroft DL, Lewis NJ, Gorman L, Akazawa S, Phillips LS, et al: The 1986 McCollum Award Lecture. Fuel-mediated teratogenesis during early organogenesis: The effects of increased concentrations of glucose, ketones, or somatomedin inhibitor during rat embryo culture. Am J Clin Nutr 1986;44:986–995.
    External Resources
  12. Eriksson U, Dahlstrom E, Larsson KS, Hellerstrom C: Increased incidence of congenital malformations in the offspring of diabetic rats and their prevention by maternal insulin therapy. Diabetes 1982;31:1–6.
  13. Nielsen GL, Sorensen HT, Nielsen PH, Sabroe S, Olsen J: Glycosylated hemoglobin as predictor of adverse fetal outcome in type 1 diabetic pregnancies. Acta Diabetol 1997;34:217–222.
  14. The Diabetes Control and Complications Trial Research Group: Pregnancy outcomes in the Diabetes Control and Complications Trial. Am J Obstet Gynecol 1996;174:1343–1353.
  15. Miller E, Hare JW, Cloherty JP, Dunn PJ, Gleason RE, Soeldner JS, et al: Elevated maternal hemoglobin A1C in early pregnancy and major congenital anomalies in infants of diabetic mothers. N Engl J Med 1981;304:1331–1334.
  16. Reid M, Hadden D, Harley JMG, Halliday HL, McClure BG: Fetal malformations in diabetics with high haemoglobin A1c in early pregnancy. BMJ 1984;289:1001.
  17. Towner D, Kjos SL, Leung B, Montoro MM, Xiang A, Mestman JH, et al: Congenital malformations in pregnancies complicated by NIDDM. Diabetes Care 1995;18:1446–1451.
  18. Kitzmiller JL, Gavin LA, Gin GD, Jovanovic-Peterson L, Main EK, Zigrang WD: Preconception care of diabetes. Glycemic control prevents congenital anomalies. JAMA 1991;265:731–736.
  19. Rosenn B, Miodovnik M, Combs A, Khoury J, Siddiqi TA: Glycemic thresholds for spontaneous abortion and congenital malformations in insulin-dependent diabetes mellitus. Obstet Gynecol 1994;84:515–520.
  20. Hanson U, Persson B, Thunell S: Relationship between haemoglobin A1C in early type 1 (insulin-dependent) diabetic pregnancy and the occurrence of spontaneous abortion and fetal malformation in Sweden. Diabetologica 1990;33:100–104.
  21. Ylinen K, Aula P, Stenman U-H, Kesaniemi-Kuokkanen T, Teramo K: Risk of minor and major fetal malformations in diabetics with high haemoglobin A1c values in early pregnancy. BMJ 1984;289:345–346.
  22. Greene MF, Hare JW, Cloherty JP, Benacerraf BR, Soeldner JS: First-trimester hemoglobin A1 and risk for major malformation and spontaneous abortion in diabetic pregnancy. Teratology 1989;39:225–232.
    External Resources
  23. Bry L, Chen PC, Sacks DB: Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 2001;47:153–163.
    External Resources
  24. Achiron R, Rotstein Z, Lipitz S, Mashiach S, Hegsh J: First trimester diagnosis of fetal congenital heart disease by transvaginal ultrasonography. Obstet Gynecol 1994;84:69–72.
  25. Bronshtein M, Zimmer EZ: Transvaginal sonographic follow-up on the formation of fetal cephalocoele at 13–19 weeks’ gestation. Obstet Gynecol 1991;78:528–530.
    External Resources
  26. Whitlow BJ, Economides DC: The optimal gestational age to examine fetal anatomy and measure nuchal translucency in the first trimester. Ultrasound Obstet Gynecol 1998;11:258.
  27. Johnson SP, Seibre NJ, Snjiders RJM, Tunkel S, Nicolaides KH: Ultrasound screening for anencephaly at 10–14 weeks of gestation. Ultrasound Obstet Gynecol 1997;9:14–16.
  28. Lin Y, Chang F, Liu C: Antenatal detection of hydranencephaly at 12 weeks, menstrual age. J Clin Ultrasound 1992;20:62–64.
  29. Sherer DM, Hearn-Stebbins B, Harvey W, Metlay LA, Abramowicz JS: Endovaginal sonographic diagnosis of iniencephalocoele apertus and craniorachischisis at 13 weeks, menstrual age. J Clin Ultrasound 1993;21:124–127.
  30. Hernadi L, Torocsik M: Screening for fetal anomalies in the 12th week of pregnancy by transvaginal sonography in an unselected population. Prenat Diagn 1997;17:753–759.
  31. Gembruch U, Knopfle G, Bald R, Hansmann M: Early diagnosis of fetal congenital heart disease by transvaginal echo. Ultrasound Obstet Gynecol 1993;3:310–317.
    External Resources
  32. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH: UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998;351:343–346.
    External Resources
  33. Souka AP, Snijders RJM, Novakov A, Soares W, Nicolaides KH: Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10–14 weeks of gestation. Ultrasound Obstet Gynecol 1998;11:391–400.
  34. Michailidis GD, Economides DL: Nuchal translucency measurement and pregnancy outcome in karyotypically normal fetuses. Ultrasound Obstet Gynecol 2001;17:102–105.
    External Resources
  35. Hyett J, Perdu M, Sharland G, et al: Using fetal nuchal translucency to screen for major congenital cardiac defects at 10–14 weeks gestation: Population-based cohort study. BMJ 1999;318:81.
  36. Haddow JE: Antenatal screening for Down’s syndrome: Where are we and where next? Lancet 1998;351:336–337.
  37. Wald NJ, George L, Smith D, Densem JW, Petterson K: Serum screening for Down’s syndrome between 8 and 14 weeks of pregnancy. Br J Obstet Gynecol 1996;103:765–767.
  38. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH: A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999;13:231–237.
  39. Brizot ML, Kuhn P, Bersinger NA, Zydias G, Snjiders RJ, Nicolaides KH: First trimester maternal serum α-fetoprotein in fetal trisomies. Br J Obstet Gynaecol 1995;102:31–34.
  40. Orlandi F, Damaini G, Hallahan TW, Krantz DA, Macri JN: First trimester screening for aneuploidy: Biochemistry and nuchal translucency. Ultrasound Obstet Gynecol 1997;10:381–386.
  41. Sandor GG, Farquarson D, Wittman B, et al: Fetal echo: Results in high-risk patients. Obstet Gynecol 1986;67:358.
    External Resources
  42. Copel JA, Pilu G, Green J, et al: Fetal echocardiographic screening for congenital heart disease: Importance of the four-chamber view. Am J Obstet Gynecol 1987;157:648.
    External Resources
  43. Callan NA, Maggio M, Steger S, Kan JS: Fetal echocardiography: Indications for referral, prenatal diagnosis and outcomes. Am J Perinatol 1991;8:390.
  44. Greene MF, Benacerraf BR: Prenatal diagnosis in diabetic gravidas: Utility of ultrasound and maternal serum α-fetoprotein screening. Obstet Gynecol 1991;77:520–524.
  45. Sancken U, Bartels I: Biochemical screening for chromosomal disorders and neural tube defects (NTD): Is adjustment of maternal α-fetoprotein (AFP) still appropriate in insulin-dependent diabetes mellitus (IDDM)? Prenat Diagn 2001;21:383–386.
  46. Smith RS, Comstock CH, Lorenz RP, Kirk JS, Lee W: Maternal diabetes mellitus: Which views are essential for fetal echo? Obstet Gynecol 1997;90:575–579.
  47. Yoo S, Lee YH, Kyoung SC, Kim D: Sequential segmental approach to fetal congenital heart disease. Cardiol Young 1999;9:430–444.
  48. Jaeggi ET, Fouron JC, Proulx F: Fetal cardiac performance in uncomplicated and well-controlled maternal type I diabetes. Ultrasound Obstet Gynecol 2001;17:311–315.
    External Resources
  49. Ray JG, O’Brien TE, Chan WS: Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: A meta-analysis. QJM 2001;94:435–444.
    External Resources
  50. Nachum Z, Ben-Shlomo I, Weiner E, Shalev E: Twice daily versus four times daily insulin dose regimens for diabetes in pregnancy: Randomized controlled trial. BMJ 1999;319:1223–1227.
  51. Mills JL, Simpson JL, Driscoll SG, Jovanovic-Peterson L, van Allen M, Aarons JH, et al: Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception. N Engl J Med 1988;319:1617–1623.
  52. Czeizel AE, Dudas I: Prevention of the first occurrence of neural tube defects by periconceptual vitamin supplementation. N Engl J Med 1992;327:1832–1835.
  53. Czeizel AE: Reduction of urinary tract and cardiovascular defects by periconceptional multivitamin supplementation. Am J Med Genet 1996;62:179–183.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: September 27, 2002
Issue release date: September 2002

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 4

ISSN: 1662-4246 (Print)
eISSN: 1662-8063 (Online)

For additional information: https://www.karger.com/PHG


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.